Arbutus Berry - Intervention Study to Evaluate the Modulation of Intestinal Microbiota and Metabolic Parameters
F4F
1 other identifier
interventional
30
1 country
1
Brief Summary
The tree that produces the arbutus berry, the strawberry tree, scientific name Arbutus unedo L., belongs to the family of Ericaceae. It exists in almost all of Southern Europe in arid and siliceous lands, in woods and forests and is very common in Portugal. Known for its use in the production of liqueurs and brandy, the arbutus berry is a fruit that can be consumed in nature or incorporated in the preparation of other foods. Arbutus berry has been attributed some properties beneficial to health given its low caloric value and its high content of vitamin C and flavonoids, which is why it is considered a good source of antioxidants. Arbutus has a high carbohydrate content (70-80% dry weight) with a relevant fiber fraction (10-30%), constituting an interesting source of vegetable protein (1-9%) and lipids (2-3%). Given this interesting nutritional composition, the hypothesis is that a daily consumption of this fruit can have an impact in health outcomes such as microbiota modulation and an improvement of metabolic parameters.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Nov 2022
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 8, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 22, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
December 22, 2022
CompletedFirst Submitted
Initial submission to the registry
March 30, 2023
CompletedFirst Posted
Study publicly available on registry
April 13, 2023
CompletedApril 13, 2023
March 1, 2023
1 month
March 30, 2023
March 30, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Changes in gut microbiota characterization
Difference in gut microbiota taxonomic characterization, from baseline to the end of intervention
14 days
Changes in gut microbiota diversity
Difference in gut microbiota Shannon index, from baseline to the end of intervention
14 days
Secondary Outcomes (14)
Changes in fasting glucose
14 days
Changes in HOMA-IR
14 days
Changes in HDL cholesterol
14 days
Changes in total cholesterol
14 days
Changes in LDL cholesterol
14 days
- +9 more secondary outcomes
Study Arms (2)
50 g arbutus berry
EXPERIMENTALconsumption of 50 g arbutus berry/day for 14 days
200 g arbutus berry
EXPERIMENTALconsumption of 200 g arbutus berry/day for 14 days
Interventions
consumption of 50 g arbutus berry/day or 200 g arbutus berry/day for 14 days
Eligibility Criteria
You may qualify if:
- Caucasian.
- Age between 18 and 50 years.
- Filling informed consent.
- Body mass index (BMI) between 18,5 kg/m2 and 25 kg/m2.
You may not qualify if:
- Arbutus berry sensibility.
- Arbutus berry daily consumption in the month before the study begin.
- Having taken antibiotics within the 6 months prior to beginning the study.
- Use of pro/prebiotics or fiber as a dietary supplement or any food/molecule that modifies intestinal transit time 6 weeks before recruitment.
- Use of laxative 6 weeks before recruitment.
- Specific nutritional therapy (e.g. high protein).
- Excessive alcohol consumption.
- Smoking.
- Diagnosis of gastrointestinal pathology, hormonal or thyroid pathology, autoimmune diseases, chronic use of corticosteroids, psychiatric disease or Diabetes Mellitus.
- Use of proton pump inhibitors, antidiabetic drugs, insulin, or statins.
- Pregnant or breastfeeding.
- Participation in another clinical trial within the last 3 months.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Nova Medical School Universidade Nova de Lisboa
Lisbon, 1169-056, Portugal
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Ana Faria, PhD
Universidade Nova de Lisboa
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 30, 2023
First Posted
April 13, 2023
Study Start
November 8, 2022
Primary Completion
December 22, 2022
Study Completion
December 22, 2022
Last Updated
April 13, 2023
Record last verified: 2023-03
Data Sharing
- IPD Sharing
- Will not share